ATTENTION help needed NOW hear this....NYT has pub

ATTENTION help needed
NOW hear this ....NYT has published article discussing P53 and did not mention CTIX...our board member and SA author KarinCA has posted a correction to the article...please visit NYT and reccommend/vote for/like/tweet her remarks...biomanbaba
http://www.nytimes.com/2012/12/23/health/new-...l&_r=0

comment

KarinCA
California

Cellceutix (CTIX.OB) has an ongoing trial on humans at Harvard's Dana Farber that is seeking to establish safety with efficacy as a secondary objective.

See trial info at FDA site:
Clinical trials: http://clinicaltrials.gov/ct2/show/nct0166400...rin+rank=1

The first cohort of patients have completed the first cycle without any toxic side effects. The safety committee has approved continuation of treatment for the first cohort and the 2nd cohort started this week at double the dose.

The company has a pipeline of 8 drugs and will most likely ended up being bought out by the likes of a Pfizer, Roche, or Merck. Time will tell. But, I'm sure the big boys are watching this research on kevetrin very closely.

Read about kevetrin. It's very enlightening along with being full of promise.
http://cellceutix.com/kevetrin/

Watch Cellceutix Closely For Potential Catalysts In 2013
http://seekingalpha.com/article/1054991-watch...-for-pot...

Dec. 22, 2012 at 2:32 p.m.
Reply
Recommend